

f l a a l t as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, a bank manager, solicitor, professional accountant or other professional adviser.

f l a t a f all your shares in Hospital Corporation of China Limited 弘和仁愛醫療集團有限公司, you should at once hand this circular, together with the enclosed form of proxy, to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

---



p t a C p a t f C a t  
弘和仁愛醫療集團有限公司  
( l c l )  
( t k 3 6 )

R N A C R C A R N R A N  
D A N N N D R C R  
AND  
N A N C A N N A N R A N

---

**tt f t a**

1. Introduction . . . . .	1
2. Amendment to the Proposed Resolution No. 3 of the Original Notice . . . . .	2
3. Supplemental Notice of Annual General Meeting and Revised Proxy Form. . . . .	notice S 3 6 2 - 3 6 5 . 7

In view of the ongoing COVID-19 pandemic and the heightened requirements for prevention and control of its spread, the Company will implement the following precautionary measures at the Annual General Meeting to protect attending Shareholders, staff and other stakeholders from the risk of infection:

1. Compulsory body temperature screening or checks will be carried out on every Shareholder, proxy and other attendee at the entrance of the Annual General Meeting venue. Any person with a body temperature of over 37 degrees Celsius or who is exhibiting flu-like symptoms may be denied entry into the Annual General Meeting venue and be requested to leave the Annual General Meeting venue.
2. Every attendee will be required to wear a surgical face mask throughout the Annual General Meeting. Please note that no surgical face masks will be provided at the Annual General Meeting venue and attendees should bring and wear their own surgical face masks.
3. No refreshments will be served to attendees at the Annual General Meeting.
4. No corporate gifts will be distributed to attendees at the Annual General Meeting.

Attendees are requested to observe and practice good personal hygiene at all times at the venue of the Annual General Meeting.



Public Company  
**弘和仁愛醫療集團有限公司**  
 (Incorporated in the Cayman Islands)  
 (Stock Code 36)

Executive Director:  
 Mr. Chen Shuai  
 (Chief Executive Officer)  
 Mr. Lu Wenzuo

• :  
 Maples Corporate Services Limited  
 PO Box 309, Ugland House  
 Grand Cayman, KY1-1104  
 Cayman Islands

Independent Director:  
 Mr. Su Zhiqiang  
 Ms. Shi Wenting  
 Ms. Liu Lu  
 Ms. Wang Nan

Head Office:  
 1602, Tower B  
 Jin Qiu International Building  
 No. 6, Zhichun Road, Haidian District  
 Beijing, PRC

Independent Director:  
 Mr. Dang Jinxue  
 Mr. Shi Luwen  
 Mr. Zhou Xiangliang

Board Headquarters:  
 Suite 10, 70/F.  
 Two International Finance Centre  
 No. 8 Finance Street  
 Central  
 Hong Kong

May 31, 2021

Dear Sir/Madam,

NON-CONCURRENT ANNOUNCEMENT  
 AND  
 NON-ANNOUNCEMENT

1. NON-CONCURRENT ANNOUNCEMENT

This supplemental circular should be read together with the circular of the Company dated April 28, 2021 (“**Annual Circular**”) which contains, among others, the notice of the Annual General Meeting (“**Annual Meeting**”). Unless otherwise defined, capitalised terms used in this supplemental circular shall have the same meanings as those defined in the Original Circular.

The purpose of this supplemental circular is to provide you with information regarding the changes in the proposed appointment of new Director subsequent to the despatch of the Original Circular, and to set out the supplemental notice of the Annual General Meeting (the “**Supplemental Notice**”) and the special arrangements about completion and submission of the revised proxy form (the “**Revised Proxy Form**”).

## **2. AND NON-EXECUTIVE DIRECTOR RESOLUTION NO. 3 RE NA NC**

As stated in the Original Circular, the Board had resolved to propose to appoint Mr. Pu Chengchuan (“**浦成川**”) as a non-executive Director at the Annual General Meeting pursuant to resolution numbered 3 set out in the Original Notice (“**Resolution No. 3**”). Due to changes in the intended scope of work of Mr. Pu subsequent to the despatch of the Original Circular, the Board resolved to propose to appoint Mr. Pu as an executive Director, instead of a non-executive Director at the Annual General Meeting. As such, Resolution No. 3 should be deleted in its entirety and replaced by the new resolution numbered 3 as set out in the Supplemental Notice.

Please refer to Appendix I to the Original Circular for the biography and details of Mr. Pu. Subject to Shareholders’ approval, Mr. Pu will enter into a service contract (instead of an appointment letter) with the Company for an initial term of three years commencing from the date on which the approval is obtained from the Annual General Meeting, and he is subject to retirement by rotation and re-election at least once every three years at the annual general meeting of the Company in accordance with the provisions of the Articles of Association. Mr. Pu will not receive any remuneration for acting as an executive Director.

Save for the changes set out above, there are no other changes to the Original Circular which need to be brought to the Shareholders’ attention. The remaining resolutions to be voted upon at the Annual General Meeting remain unchanged.

Whether or not you are able to attend the Annual General Meeting, you are requested to complete the Revised Proxy Form in accordance with the instructions printed thereon and return it to the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited (" **a R t a** ") at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong at a time in any event not later than 48 hours before the time appointed for holding of the Annual General Meeting or any adjournment thereof ("C

"). Completion and returning of the Revised Proxy Form will not preclude you from attending and voting in person at the Annual General Meeting or any adjournment thereof should you so wish.

A Shareholder who has not yet lodged the Original Proxy Form with the Share Registrar is requested to lodge the Revised Proxy Form if (if)-318.8((if)-roxy)-40-relodge t.4(for)-318.8(tprm)-(ies346.9(1

**4. R C NDA N**

In addition to the recommendation contained in the Original Circular, the Directors consider that the proposed appointment of Mr. Pu as an executive Director as set out in this supplemental circular is in the best interest of the Company and the Shareholders as a whole. The Directors therefore recommend the Shareholders to vote in favour of the relevant resolution to be proposed at the Annual General Meeting.

Yours faithfully,

For and on behalf of the Board  
p ta C p at f C a t  
弘和仁愛醫療集團有限公司  
C La  
C A C E ●

H K E C L E H K  
L



p ta C p at f C a t  
弘和仁愛醫療集團有限公司  
(I C I )  
( t k 3 6 )

Reference is made to the notice of annual general meeting (the “ a N t ”) of Hospital Corporation of China Limited 弘和仁愛醫療集團有限公司 (the “C pa ”) dated April 28, 2021, by which the Company convenes an annual general meeting (the “ t ”) to be held at 1602, Tower B, Jin Qiu International Building, No. 6, Zhichun Road, Haidian District, Beijing, PRC on June 22, 2021 at 3:00 p.m. and this supplemental notice shall be read together with the Original Notice.

Supplemental notice is hereby given that the Meeting will be convened as originally scheduled. Due to the matters as set out in the supplemental circular of the Company dated May 31, 2021, the resolution numbered 3 in the Original Notice should be deleted in its entirety and replaced by the following new resolution numbered 3:

“3. To appoint Mr. Pu Chengchuan as an executive Director.”

Apart from the amendment set out above, all the information contained in the Original Notice shall remain to have full force and effect.

For and on behalf of the Board  
p ta C p at f C a t  
弘和仁愛醫療集團有限公司  
C La  
C A C E ●

May 31, 2021



- .
1. A revised proxy form (the “**R**”) containing the revised resolution numbered 3 is enclosed with the supplemental circular dated May 31, 2021 (the “**Supplemental Circular**”). Please refer to the section headed “3. Supplemental Notice of Annual General Meeting and Revised Proxy Form” on pages 5 to 6 of the Supplemental Circular and the notes to the Revised Proxy Form for arrangements about the completion and submission of the Revised Proxy Form.